Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2025 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de service
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to The Report
Biotech

Incyte

Incyte raises $25B Public at $28B valuation

$25B
Total Raised
Public
Latest Round
1991
Founded
2500+
Employees
1801 Augustine Cut-Off, Wilmington, DE 19803
Updated January 1, 2024
1 min read

Quick Facts

Valuation
$28B
Latest Round Size
$25B
Latest Round Date
January 2024

Incyte: Public Funding Round

Incyte has successfully raised $25B in Public funding, reaching a valuation of $28B.

Company Overview

Biopharmaceutical company

Funding Details

The Public round was led by Public.

Company Information

  • Headquarters: 1801 Augustine Cut-Off, Wilmington, DE 19803
  • Founded: 1991
  • Employees: 2500+
  • Category: Biotech

Investment

Incyte plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Public: Verified investor in Public

Key Investors

Public
Lead Investor
Verified investor in Public

Topics

verified(3079)real-funding(3079)public(927)incytebiotech1801-augustine-cut-off

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M